AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17243360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pianists
Number of subjects: 0
Study 17243360 — intervention group
Group type: COMPARATOR
Intervention: Nonpianists
Number of subjects: 0
Study 17243360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 14672295 — intervention group
Group type: COMPARATOR
Intervention: Milk group
Number of subjects: 0
Study 14672295 — intervention group
Group type: COMPARATOR
Intervention: Meat group
Number of subjects: 0
Study 14672295 — intervention group
Group type: COMPARATOR
Intervention: Energy group
Number of subjects: 0
Study 10950228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine treatment (2 microg/kg bodyweight on day 1, 1 microg/kg bodyweight on subsequent days up to 12 days)
Number of subjects: 40
Study 10950228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine treatment
Number of subjects: 40
Study 10950228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 8973709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA mutation at nucleotide 1555
Number of subjects: 7
Study 1282179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg b.i.d. increased to 20 mg b.i.d. after 4 weeks)
Number of subjects: 58
Study 1282179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg b.i.d.)
Number of subjects: 58
Study 1282179 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 58
Study 1282179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Nicorandil and Nifedipine)
Number of subjects: 58
Study 1282179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg)
Number of subjects: 58
Study 6429850 — intervention group
Group type: EXPERIMENTAL
Intervention: AIO solution (40 g crystalline L-aminoacids, 38 g fat, 75 g sorbitol, 45 g xylitol in 1000 ml)
Number of subjects: 20
Study 6429850 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN (glucose and aminoacids)
Number of subjects: 20
Study 6429850 — intervention group
Group type: EXPERIMENTAL
Intervention: AIO solution
Number of subjects: 20
Study 6429850 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN
Number of subjects: 20
Study 30534946 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 5050
Study 30534946 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 5050
Study 30399503 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTI with RISE‐UP routine
Number of subjects: 40
Study 30399503 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 40
Study 26519435 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention
Number of subjects: 89
Study 26519435 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening intervention
Number of subjects: 89
Study 26519435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both music interventions
Number of subjects: 89
Study 26519435 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 89
Study 24748778 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Monitoring Unit (GMU)
Number of subjects: 320
Study 24748778 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 320
Study 24748778 — intervention group
Group type: COMPARATOR
Intervention: Pre-GMU
Number of subjects: 320
Study 24748778 — intervention group
Group type: EXPERIMENTAL
Intervention: GMU
Number of subjects: 320
Study 23322551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 17
Study 23322551 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study 20536366 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B at 0.7 mg/kg/day
Number of subjects: 267
Study 20536366 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 3 mg/kg/day
Number of subjects: 267
Study 20536366 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 6 mg/kg/day
Number of subjects: 267
Study 18685549 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual anal sex activity
Number of subjects: 2357
Study 18685549 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use during anal sex
Number of subjects: 2357
Study 18685549 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk behaviors associated with anal sex
Number of subjects: 2357
Study 18685549 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use for anal sex
Number of subjects: 2357
Study 15619152 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM didactic presentation
Number of subjects: 96
Study 15619152 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group seminars
Number of subjects: 96
Study 15619152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modalities (CD-ROM + small-group seminars)
Number of subjects: 96
Study 14964349 — intervention group
Group type: EXPERIMENTAL
Intervention: nonretarded test medication
Number of subjects: 18
Study 14964349 — intervention group
Group type: COMPARATOR
Intervention: retarded reference formulation
Number of subjects: 18
Study 14964349 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 18
Study 10642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilizing therapy and first transplant
Number of subjects: 21
Study 10642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilizing regimen
Number of subjects: 21
Study 10642807 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related chemotherapy
Number of subjects: 21
Study 8886748 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine plus vitamin B6/B12
Number of subjects: 24
Study 2062997 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days supply of medication
Number of subjects: 0
Study 2062997 — intervention group
Group type: COMPARATOR
Intervention: 14 days supply of medication
Number of subjects: 0
Study 2062997 — intervention group
Group type: EXPERIMENTAL
Intervention: New discharge letter with prescription details
Number of subjects: 0
Study 2994386 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy/10 fractions/2 weeks
Number of subjects: 69
Study 2994386 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy/20 fractions/4 weeks
Number of subjects: 69
Study 30883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure to Silcton landmarks
Number of subjects: 0
Study 30883177 — intervention group
Group type: COMPARATOR
Intervention: Control landmarks on the university campus
Number of subjects: 0
Study 30883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity with landmarks
Number of subjects: 0
Study 30883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in direction estimation
Number of subjects: 0
Study 30883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective taking ability
Number of subjects: 0
Study 30570797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supportive supervision of lady health workers (LHWs) by lady health supervisors, including enhanced training on supervisory skills and written feedback.
Number of subjects: 34
Study 30570797 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison arm) with standard supervision without enhanced training or feedback.
Number of subjects: 34
Study 27160060 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance contingent reward
Number of subjects: 0
Study 27160060 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contingent reward
Number of subjects: 0
Study 25407966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (radiotherapy + LMP1-targeted DNAzyme)
Number of subjects: 24
Study 25407966 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone group (radiotherapy + normal saline)
Number of subjects: 24
Study 25407966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 22607866 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V (everolimus-eluting stent, EES)
Number of subjects: 324
Study 22607866 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Liberté (paclitaxel-eluting stent, PES)
Number of subjects: 324
Study 20337664 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow graft
Number of subjects: 13
Study 20337664 — intervention group
Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 13
Study 23135655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil Dermacontrol Moisturizer (CDM) + tretinoin cream 0.05%
Number of subjects: 0
Study 23135655 — intervention group
Group type: COMPARATOR
Intervention: tretinoin cream 0.05%
Number of subjects: 0
Study 15883262 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg; two 40‐mg tablets once daily)
Number of subjects: 67
Study 15883262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15883262 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 67
Study 12623831 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% 2D
Number of subjects: 15
Study 12623831 — intervention group
Group type: COMPARATOR
Intervention: latanoprost 0.005% 2D
Number of subjects: 15
Study 9607039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 001)
Number of subjects: 0
Study 9607039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 003)
Number of subjects: 0
Study 9607039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine
Number of subjects: 0
Study 7649608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenonium bromide
Number of subjects: 6
Study 7649608 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Number of subjects: 6
Study 7649608 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 6
Study 7649608 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 6
Study 2667153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice a day for seven days)
Number of subjects: 188
Study 2667153 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg twice a day for seven days)
Number of subjects: 188
Study 790287 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized isoproterenol
Number of subjects: 12
Study 790287 — intervention group
Group type: COMPARATOR
Intervention: Oral theophylline (10 mg/kg three times per day)
Number of subjects: 12
Study 790287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31230766 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (140Hz, 400μs, 33mJ)
Number of subjects: 0
Study 31230766 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (35Hz, 297μs, 200mJ, air‐water cooling)
Number of subjects: 0
Study 31230766 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (15c blade)
Number of subjects: 0
Study 31876726 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 74
Study 31876726 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane block (TAPB)
Number of subjects: 74
Study 28551198 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent discouragement of child anger
Number of subjects: 92
Study 28551198 — intervention group
Group type: EXPERIMENTAL
Intervention: Child anger intensity
Number of subjects: 92
Study 25376189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine eye drops
Number of subjects: 20
Study 25376189 — intervention group
Group type: COMPARATOR
Intervention: 25% dextrose orally
Number of subjects: 20
Study 23483198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.25 mg)
Number of subjects: 16
Study 23483198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21993434 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoodia gordonii purified extract (HgPE) 1110 mg, 2 servings/day for 15 days
Number of subjects: 49
Study 21993434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 21993434 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoodia gordonii purified extract (HgPE)
Number of subjects: 49
Study 18434719 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2422
Study 18434719 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2422
Study 16563397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) pregnancies
Number of subjects: 351
Study 12659615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 838
Study 12659615 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 838
Study 10632129 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO beverage
Number of subjects: 63
Study 10632129 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 63
Study 10632129 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage and Placebo beverage
Number of subjects: 63
Study 8813793 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status measurement (serum concentration of iron, transferrin saturation, TIBC)
Number of subjects: 36
Study 8813793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hypoferraemia response
Number of subjects: 36
Study 8813793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoferraemia degree
Number of subjects: 36
Study 8813793 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sequestration recognition
Number of subjects: 36
Study 1382540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy, keratolytic wart paint, and paring
Number of subjects: 400
Study 1382540 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy and inosine pranobex 60 mg/kg/day for 1 week each month
Number of subjects: 400
Study 1382540 — intervention group
Group type: EXPERIMENTAL
Intervention: Paring
Number of subjects: 400
Study 3886023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 plus magnesium
Number of subjects: 60
Study 3886023 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6
Number of subjects: 60
Study 3886023 — intervention group
Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 60
Study 30507409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 2029
Study 30507409 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2029
Study 26752328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual in vivo exposure therapy (iVET)
Number of subjects: 60
Study 26752328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual virtual reality exposure therapy (VRET)
Number of subjects: 60
Study 26752328 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list
Number of subjects: 60
Study 24067301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 24067301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 22343689 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml fibrin sealant
Number of subjects: 90
Study 22343689 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml fibrin sealant
Number of subjects: 90
Study 22343689 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 20738234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge orthoses (5 degrees)
Number of subjects: 8
Study 20738234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge orthoses (8.5 degrees)
Number of subjects: 8
Study 20738234 — intervention group
Group type: COMPARATOR
Intervention: No wedge
Number of subjects: 8
Study 18726956 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure application for hemostasis (Group I)
Number of subjects: 436
Study 18726956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure application confirming radial artery patency using Barbeau's test (Group II)
Number of subjects: 436
Study 15883277 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for choroidal melanoma
Number of subjects: 2320
Study 15883277 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 2320
Study 15883277 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 2320
Study 12374512 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with antihypertensive therapy (nitrendipine 10-40 mg/d, possibly with enalapril maleate 5-20 mg/d and/or hydrochlorothiazide 12.5-25 mg/d)
Number of subjects: 2902
Study 12374512 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 2902
Study 12374512 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with antihypertensive therapy
Number of subjects: 2902
Study 10469764 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 1721
Study 10469764 — intervention group
Group type: COMPARATOR
Intervention: RSVIG
Number of subjects: 1721
Study 10469764 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1721
Study 7491805 — intervention group
Group type: EXPERIMENTAL
Intervention: new measuring device for intraoperative leg length assessment
Number of subjects: 53
Study 29843323 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 209
Study 29843323 — intervention group
Group type: COMPARATOR
Intervention: Ethacridine dye (Emcredil®)
Number of subjects: 209
Study 376098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG (IL-BCG)
Number of subjects: 59
Study 376098 — intervention group
Group type: COMPARATOR
Intervention: Multiple puncture vaccination BCG (MPV-BCG)
Number of subjects: 59
Study 30499618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU daily)
Number of subjects: 104
Study 30499618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus Calcium (1200 mg daily)
Number of subjects: 104
Study 28333510 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD treatment (medication + parent training)
Number of subjects: 216
Study 28333510 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading treatment (reading instruction)
Number of subjects: 216
Study 28333510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ADHD + reading treatment
Number of subjects: 216
Study 26786351 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 70
Study 26786351 — intervention group
Group type: COMPARATOR
Intervention: Conventional low‐fat diet (LFD)
Number of subjects: 70
Study 25092686 — intervention group
Group type: EXPERIMENTAL
Intervention: β-adrenergic antagonist propranolol
Number of subjects: 15
Study 25092686 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 15
Study 25092686 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM subjects
Number of subjects: 15
Study 21779819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 4216
Study 21779819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40/20 mg
Number of subjects: 4216
Study 21779819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg (higher-risk subgroup)
Number of subjects: 4216
Study 21779819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 and 40/20 mg (combined data)
Number of subjects: 4216
Study 21779819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 4216
Study 21779819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4216
Study 19171224 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-inhibitory doses of aspirin (maximal total dose: 400mg/day)
Number of subjects: 70
Study 19171224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17685716 — intervention group
Group type: EXPERIMENTAL
Intervention: Incline treadmill training
Number of subjects: 31
Study 17685716 — intervention group
Group type: COMPARATOR
Intervention: Ground-based resistive training
Number of subjects: 31
Study 15826746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscular monthly)
Number of subjects: 60
Study 15826746 — intervention group
Group type: COMPARATOR
Intervention: Calcium and cholecalciferol (500 mg of elemental calcium and 400 IU cholecalciferol daily)
Number of subjects: 60
Study 15826746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscular monthly) with calcium and cholecalciferol
Number of subjects: 60
Study 12547448 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9154784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular 3-0 polyglactin 910 sutures
Number of subjects: 54
Study 9154784 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous 3-0 nylon sutures
Number of subjects: 54
Study 9154784 — intervention group
Group type: COMPARATOR
Intervention: Adhesive strips
Number of subjects: 54
Study 8199810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 60 mg/kg infused intravenously
Number of subjects: 20
Study 8199810 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 3597737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (125 transfers)
Number of subjects: 258
Study 3597737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (133 transfers)
Number of subjects: 258
Study 31874497 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7438135 locus in UGT2B7 gene
Number of subjects: 50
Study 31874497 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3732765 locus in P2RY12 gene
Number of subjects: 50
Study 31874497 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7438135 GA genotype
Number of subjects: 50
Study 29914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Jawbone UP3
Number of subjects: 78
Study 29914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge Heart Rate
Number of subjects: 78
Study 29914050 — intervention group
Group type: EXPERIMENTAL
Intervention: SenseWear Armband
Number of subjects: 78
Study 29914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart
Number of subjects: 78